| Nome |
# |
|
Global multi-stakeholder endorsement of the MAFLD definition, file e268c4ce-e454-a6b7-e053-3a05fe0adea1
|
2.355
|
|
Is there an "ideal" diet for patients with NAFLD?, file e268c4ce-1b37-a6b7-e053-3a05fe0adea1
|
363
|
|
EASL Clinical Practice Guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis, file e268c4ce-c117-a6b7-e053-3a05fe0adea1
|
262
|
|
Improvement in Waldenstrom’s macroglobulinemia after successful treatment of HCV with direct-acting antivirals, file e268c4c9-bf29-a6b7-e053-3a05fe0adea1
|
174
|
|
Influence of HIV Infection on the Natural History of Hepatocellular Carcinoma: Results From a Global Multicohort Study, file e268c4ca-25c2-a6b7-e053-3a05fe0adea1
|
150
|
|
Low Fibrinogen Levels Are Associated with Bleeding After Varices Ligation in Thrombocytopenic Cirrhotic Patients, file e268c4ca-25ab-a6b7-e053-3a05fe0adea1
|
143
|
|
Acquired Hepatocerebral Degeneration in the Absence of Portosystemic Shunting, file e268c4ca-23d9-a6b7-e053-3a05fe0adea1
|
117
|
|
Long term results of down-staging and liver transplantation for patients with hepatocellular carcinoma beyond the conventional criteria, file e268c4ca-77c5-a6b7-e053-3a05fe0adea1
|
101
|
|
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study, file e268c4cb-7870-a6b7-e053-3a05fe0adea1
|
99
|
|
An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs, file e268c4ce-884f-a6b7-e053-3a05fe0adea1
|
93
|
|
Concepts and Controversies in Haemostasis and Thrombosis Associated with Liver Disease: Proceedings of the 7th International Coagulation in Liver Disease Conference, file e268c4ca-23e5-a6b7-e053-3a05fe0adea1
|
90
|
|
Laser ablation is superior to TACE in large-sized hepatocellular carcinoma: A pilot case-control study, file e268c4ca-7aef-a6b7-e053-3a05fe0adea1
|
89
|
|
Mediterranean Diet and NAFLD: What We Know and Questions That Still Need to Be Answered, file e268c4cb-c55c-a6b7-e053-3a05fe0adea1
|
87
|
|
A Liver Index and its Relationship to Indices of HCC Aggressiveness, file e268c4ca-41f1-a6b7-e053-3a05fe0adea1
|
84
|
|
Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network, file e268c4ca-433f-a6b7-e053-3a05fe0adea1
|
82
|
|
A summary of the 6th international conference on coagulation in liver disease: Discussion, debate, deliberations, file e268c4ca-5747-a6b7-e053-3a05fe0adea1
|
81
|
|
Non-cirrhotic thrombocytopenic patients with hepatitis C virus: characteristics and outcome of antiviral therapy., file e268c4ca-7b09-a6b7-e053-3a05fe0adea1
|
78
|
|
Plasma cholesterol and lipoprotein levels in relation to tumor aggressiveness and survival in HCC patients, file e268c4ca-7939-a6b7-e053-3a05fe0adea1
|
77
|
|
Development and validation of a new prognostic system for patients with hepatocellular carcinoma., file e268c4ca-31b1-a6b7-e053-3a05fe0adea1
|
75
|
|
Platelets and Hepatocellular Cancer: Bridging the Bench to the Clinics, file e268c4cb-53ba-a6b7-e053-3a05fe0adea1
|
75
|
|
Optimal management of constipation associated with irritable bowel syndrome., file e268c4ca-7d60-a6b7-e053-3a05fe0adea1
|
74
|
|
Eradication of hepatitis C virus infection disclosing a previously hidden, underlying autoimmune hepatitis: Autoimmune hepatitis and HCV, file e268c4cb-eb3c-a6b7-e053-3a05fe0adea1
|
74
|
|
An HCC Aggressiveness Index and Blood GTP, Bilirubin and Platelet Levels, file e268c4ca-5b01-a6b7-e053-3a05fe0adea1
|
72
|
|
Vonoprazan Fumarate for the Treatment of Gastric Ulcers: A Short Review on Emerging Data, file e268c4cb-ec49-a6b7-e053-3a05fe0adea1
|
71
|
|
Overview of Immune Checkpoint Inhibitors Therapy for Hepatocellular Carcinoma, and The ITA.LI.CA Cohort Derived Estimate of Amenability Rate to Immune Checkpoint Inhibitors in Clinical Practice, file e268c4cb-28d4-a6b7-e053-3a05fe0adea1
|
70
|
|
Surveillance for Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease: Universal or Selective?, file e268c4cc-7530-a6b7-e053-3a05fe0adea1
|
57
|
|
Starry Liver: An Unexpected Diagnosis, file e268c4ca-5b0b-a6b7-e053-3a05fe0adea1
|
56
|
|
Corrigendum to ‘An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs’ [J Hepatol 2021;75(3):572–581] (Journal of Hepatology (2021) 75(3) (572–581), (S0168827821003342), (10.1016/j.jhep.2021.04.055)), file e268c4ce-55e9-a6b7-e053-3a05fe0adea1
|
49
|
|
Transarterial Chemoembolization for Hepatocellular Carcinoma in Clinical Practice: Temporal Trends and Survival Outcomes of an Iterative Treatment, file e268c4ce-2b07-a6b7-e053-3a05fe0adea1
|
44
|
|
Need for independence of treatment allocation from prognostic evaluation for hepatocellular carcinoma, file e2b30931-3685-49d6-9bb8-957acdf3a4b6
|
30
|
|
Treatment allocation in patients with hepatocellular carcinoma: Need for a paradigm shift?, file e268c4ce-f823-a6b7-e053-3a05fe0adea1
|
17
|
|
The Hepatologist in the Haematologist Field: a Rare Cause of Non-Cirrhotic Portal Hypertension, file e268c4ca-b071-a6b7-e053-3a05fe0adea1
|
11
|
|
Peripheral blood cytopaenia limiting initiation of treatment in chronic hepatitis C patients otherwise eligible for antiviral therapy, file e268c4c6-c757-a6b7-e053-3a05fe0adea1
|
8
|
|
Breath tests to assess alcoholic liver disease., file e268c4ca-19dc-a6b7-e053-3a05fe0adea1
|
6
|
|
The ITA.LI.CA Consortium: how multicentre collaboration helped shape the management of patients with hepatocellular carcinoma on the basis of real-world evidence, file e268c4ce-2b05-a6b7-e053-3a05fe0adea1
|
6
|
|
May an aspirin a day truly take hepatocellular carcinoma away?, file 95ef4970-767c-4e8b-b3a1-24ae0a9f5aaa
|
5
|
|
The role of small intestinal bacterial overgrowth in cystic fibrosis: a randomized case-controlled clinical trial with rifaximin, file e268c4ca-23d3-a6b7-e053-3a05fe0adea1
|
5
|
|
Immunoglobulin, nucleos(t)ide analogs and hbv recurrence after liver transplant: a meta‐analysis, file e268c4ce-0cc5-a6b7-e053-3a05fe0adea1
|
5
|
|
Appropriateness of proton pump inhibitors treatment in clinical practice: Prospective evaluation in outpatients and perspective assessment of drug optimisation, file e268c4cc-848a-a6b7-e053-3a05fe0adea1
|
4
|
|
Risk factors for bleeding following oesophageal band ligation: Providing further evidence to ameliorate clinical practice, file e268c4cc-9f63-a6b7-e053-3a05fe0adea1
|
4
|
|
Procedure-related bleeding risk in patients with cirrhosis and severe thrombocytopenia, file e268c4cd-bf59-a6b7-e053-3a05fe0adea1
|
4
|
|
Elevated adherence to vaccination against SARS-CoV-2 among patients with Inflammatory Bowel Disease, file e268c4ce-6ae0-a6b7-e053-3a05fe0adea1
|
4
|
|
Response to COVID-19 Vaccination in Patients with Inflammatory Bowel Disease on Biological Treatment, file e268c4ce-d514-a6b7-e053-3a05fe0adea1
|
4
|
|
Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study., file e268c4c6-b35b-a6b7-e053-3a05fe0adea1
|
3
|
|
Treatment of early stage chronic hepatitis C virus infection, file e268c4ca-2201-a6b7-e053-3a05fe0adea1
|
3
|
|
NASH-related and cryptogenic cirrhosis similarities extend beyond cirrhosis, file e268c4ca-23db-a6b7-e053-3a05fe0adea1
|
3
|
|
Prognosis of untreated hepatocellular carcinoma., file e268c4ca-25b7-a6b7-e053-3a05fe0adea1
|
3
|
|
Letter: faecal volatile organic metabolites, promising biomarkers in inflammatory bowel disease., file e268c4ca-31af-a6b7-e053-3a05fe0adea1
|
3
|
|
Improvement in hepatitis C virus patients with advanced, compensated liver disease after sustained virological response to direct acting antivirals, file e268c4ca-77c7-a6b7-e053-3a05fe0adea1
|
3
|
|
Harmonising proton pump inhibitors treatment in the specialist setting following the SIGE recommendations, file e268c4ca-77c9-a6b7-e053-3a05fe0adea1
|
3
|
|
Letter: it is time to adopt new objective parameters to accurately identify patients with functional heartburn, file e268c4ca-7937-a6b7-e053-3a05fe0adea1
|
3
|
|
Bleeding after paracentesis in patients with decompensated cirrhosis and acute kidney injury: the perfect storm, file e268c4ca-7af6-a6b7-e053-3a05fe0adea1
|
3
|
|
Comparison of Two Different Techniques to Assess Adalimumab Trough Levels in Patients with Crohn's Disease., file e268c4ca-7ce2-a6b7-e053-3a05fe0adea1
|
3
|
|
Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN), file e268c4ca-7f28-a6b7-e053-3a05fe0adea1
|
3
|
|
Regression of Fibrosis After DAAs Treatment of Patients with HCV Cirrhosis: Transposability to Non-Decompensated Patients, file e268c4ca-aac5-a6b7-e053-3a05fe0adea1
|
3
|
|
Identification of clinical phenotypes and related survival in patients with large hccs, file e268c4cd-38f5-a6b7-e053-3a05fe0adea1
|
3
|
|
Proactive Measures Aimed at Improving Appropriateness of Use of Proton Pump Inhibitors in Clinical Practice, file e268c4cd-7fe9-a6b7-e053-3a05fe0adea1
|
3
|
|
Bleeding Events in Lusutrombopag-treated Thrombocytopoenic Patients, file e268c4cd-bf5d-a6b7-e053-3a05fe0adea1
|
3
|
|
Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors and Applicability of First-Line Atezolizumab/Bevacizumab in a Real-Life Setting, file e268c4cd-cf16-a6b7-e053-3a05fe0adea1
|
3
|
|
A Nomogram-Based Prognostic Model for Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib: A Multicenter Study, file e268c4cd-eee5-a6b7-e053-3a05fe0adea1
|
3
|
|
Recalibrating survival prediction among patients receiving trans‐arterial chemoembolization for hepatocellular carcinoma, file e268c4cd-f8c5-a6b7-e053-3a05fe0adea1
|
3
|
|
Obeticholic Acid Improves Aminotransferases Early during Treatment in Patients with Primary Biliary Cholangitis Not Responding to Ursodeoxycholic Acid: A Study in Clinical Practice, file e268c4ce-5543-a6b7-e053-3a05fe0adea1
|
3
|
|
Prevalence of Lactose Intolerance in Patients with Hashimoto Thyroiditis and Impact on LT4 Replacement Dose, file 47bf2204-cd0a-40b6-8f31-950c92ff5486
|
2
|
|
Diabetes Medications and Risk of Hepatocellular Carcinoma, file 62fb5a1a-8154-4633-929b-6d0573aafd9e
|
2
|
|
Colorectal Cancer in Inflammatory Bowel Diseases: Epidemiology and Prevention: A Review, file 7ae9f4ca-2f3c-4078-8de4-a69fab74705d
|
2
|
|
Reply: novel antidiabetic drugs and the risk for hepatocellular carcinoma. What else to expect from these "wonderful" drug classes?, file 7c4932a1-d1af-4073-9d87-e80e2b37e194
|
2
|
|
Letter to the Editor: Objective evaluation of liver steatosis in donor organs-Potential usefulness of noninvasive assessment, file d65f23c8-269d-41ea-83c9-3579b1213ffa
|
2
|
|
Hepatic Decompensation is the Major Driver of Death In HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma, file e268c4ca-1a38-a6b7-e053-3a05fe0adea1
|
2
|
|
A Nodule, is a Nodule, is a Nodule: May Alpha-fetoprotein Make the Difference?, file e268c4ca-4c4d-a6b7-e053-3a05fe0adea1
|
2
|
|
Application of the intermediate stage sub-classification to patients with untreated hepatocellular carcinoma, file e268c4ca-5dc1-a6b7-e053-3a05fe0adea1
|
2
|
|
Infliximab trough levels and persistent vs transient antibodies measured early after induction predict long-term clinical remission in patients with inflammatory bowel disease, file e268c4ca-7ead-a6b7-e053-3a05fe0adea1
|
2
|
|
Clinical trial: the combination of rifaximin with partially hydrolysed guar gum is more effective than rifaximin alone in eradicating small intestinal bacterial overgrowth., file e268c4ca-bfcf-a6b7-e053-3a05fe0adea1
|
2
|
|
Hepatocellular carcinoma is the most frequent final diagnosis of focal liver lesions identified in a cross-sectional evaluation of patients with chronic liver disease in Saudi Arabia., file e268c4cb-debd-a6b7-e053-3a05fe0adea1
|
2
|
|
Surveillance as Determinant of Long-Term Survival in Non-Transplanted Hepatocellular Carcinoma Patients, file e268c4cd-8fe1-a6b7-e053-3a05fe0adea1
|
2
|
|
Nuts and Non-Alcoholic Fatty Liver Disease: Are Nuts Safe for Patients with Fatty Liver Disease?, file e268c4cd-91b6-a6b7-e053-3a05fe0adea1
|
2
|
|
Overview of Prognostic Systems for Hepatocellular Carcinoma and ITA.LI.CA External Validation of MESH and CNLC Classifications, file e268c4cd-ad22-a6b7-e053-3a05fe0adea1
|
2
|
|
Letter: predictive factors for treatment discontinuation in IBD—anti-TNF trough levels and anti-drug antibodies, file e268c4cd-b1b7-a6b7-e053-3a05fe0adea1
|
2
|
|
Effects of SARS-CoV-2 emergency measures on high-risk lesions detection: a multicentre cross-sectional study, file e268c4cd-e593-a6b7-e053-3a05fe0adea1
|
2
|
|
Applicability of Parameters for the Non-Invasive Diagnosis of Esophageal Varices Needing Treatment to Cured HCV Patients, file e268c4ce-0431-a6b7-e053-3a05fe0adea1
|
2
|
|
Dietary Management of Eosinophilic Esophagitis: Tailoring the Approach, file e268c4ce-0750-a6b7-e053-3a05fe0adea1
|
2
|
|
Prevention Strategies for Esophageal Cancer—An Expert Review, file e268c4ce-0d07-a6b7-e053-3a05fe0adea1
|
2
|
|
Changes in hepatocellular carcinoma aggressiveness characteristics with an increase in tumor diameter, file e268c4ce-1995-a6b7-e053-3a05fe0adea1
|
2
|
|
Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy, file e268c4ce-5426-a6b7-e053-3a05fe0adea1
|
2
|
|
Immune checkpoint inhibitors in malignancies after liver transplantation: a systematic review and pooled analysis, file 07f31505-3abc-4ed1-a4ae-ab2e83d20a81
|
1
|
|
Can High-Frequency Intraoral Ultrasound Predict Histological Risk Factors in Oral Squamous Cell Carcinoma? A Preliminary Experience, file 19835947-1244-4983-be7f-5d66f2b379de
|
1
|
|
HBV, antivirals, and immunoglobulins after liver transplantation: all that glitters is not gold, file 1e322448-ab42-46d1-87ae-1cbe4e6637b5
|
1
|
|
TRANSITION PROGRAMMES FOR YOUNG PATIENTS WITH INFLAMMATORY BOWEL DISEASE IMPROVE ADHERENCE TO CARE, file 28e40d53-5566-497a-b279-0a9fe40df80c
|
1
|
|
Gastrointestinal Tract Cancers, an Increasing Burden of the Modern Era: Epidemiology and Prevention, file 38479504-0ee5-432d-b7dc-41cc8be16b2a
|
1
|
|
Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma, file a65aa139-f097-48a5-8acd-b4d57df65de4
|
1
|
|
The international normalized ratio - Great for prediction of bleeding in patients taking vitamin K antagonists, useless for prediction of bleeding in patients with chronic liver disease, file b3f0ba99-1926-48ad-821e-f6181f00e845
|
1
|
|
The Italian data on SARS-CoV-2 infection in transplanted patients support an organ specific immune response in liver recipients, file b42eed48-39d1-4905-8a69-954d2f5b435e
|
1
|
|
Holistic Management of Hepatocellular Carcinoma: The Hepatologist’s Comprehensive Playbook, file c264774d-b620-484b-8088-f07be326a8a2
|
1
|
|
Primary biliary cholangitis: Perception and expectation of illness in Italian patients, file ddfc6aa1-b482-4371-b4cd-3e26ac0f9036
|
1
|
|
Combined multichannel intraluminal impedance and pH-metry: a novel technique to improve detection of gastro-oesophageal reflux literature review., file e268c4c6-10ae-a6b7-e053-3a05fe0adea1
|
1
|
|
Previous hepatitis B virus infection is associated with worse disease stage and occult hepatitis B virus infection has low prevalence and pathogenicity in hepatitis C virus-positive patients, file e268c4c7-292f-a6b7-e053-3a05fe0adea1
|
1
|
|
Reduction in TIMP-2 serum levels predicts remission of inflammatory bowel diseases, file e268c4c9-a8ef-a6b7-e053-3a05fe0adea1
|
1
|
|
A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma, file e268c4ca-18c3-a6b7-e053-3a05fe0adea1
|
1
|
|
Portal vein thrombosis and chronic liver disease progression: the closer you look the more you see., file e268c4ca-19d2-a6b7-e053-3a05fe0adea1
|
1
|
|
Prognostic role of mean platelet volume in patients with cirrhosis, file e268c4ca-19d4-a6b7-e053-3a05fe0adea1
|
1
|
|
Curative therapies are superior to standard of care(transarterial chemoembolization)for intermediate stage hepatocellular carcinoma, file e268c4ca-1a72-a6b7-e053-3a05fe0adea1
|
1
|
| Totale |
5.471 |